Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03829657 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study, sponsored by Theravance Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
NCT03829657 is a Phase 3 study that was terminated before completion, run by Theravance Biopharma. The registered enrollment target is 203 participants.
The verdict
NCT03829657, a Phase 3 study, was terminated before completion, sponsored by Theravance Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
Study Summary
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
Interventions
- DRUG Placebo
- DRUG ampreloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2021-11-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03829657
The ClinicalTrials.gov registry entry for NCT03829657 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03829657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03829657 about?
NCT03829657 is a clinical study titled "Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure". A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
What is the current status of trial NCT03829657?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2019-02-22. Estimated completion is 2021-11-10.
What interventions are being tested in trial NCT03829657?
The interventions under investigation include: Placebo (DRUG), ampreloxetine (DRUG).
Who is sponsoring clinical trial NCT03829657?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.